Content area
Full Text
Presentation
OPERATOR: Ladies and gentlemen, good day, and welcome to Cadila Healthcare Limited Q3 FY '22 Post Results Conference Call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Ganesh Nayak Executive Director at Cadila Healthcare Limited. Thank you, and over to you, sir.
GANESH NARAYAN NAYAK, COO & EXECUTIVE DIRECTOR, CADILA HEALTHCARE LIMITED: Thank you. Good evening, ladies and gentlemen. Welcome to our post results teleconference for the quarter ended December 31, 2021. I do wish that you and your families are keeping safe and well. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Vishal Gor, Senior Vice President, Corporate Finance; and Alok Garg, Senior Vice President from the Managing Directors' Office.
I'm sure you would have gone through the quarterly results investors' presentation, which we have posted on our website and filed with the stock exchanges. The quarter gone by was yet another quarter of robust performance for our human health formulations business in India. The branded generics portfolio delivered a strong double-digit growth during the quarter. In fact, this is the fourth consecutive quarter of strong growth for our branded formulations business in India. With the reduced need of COVID-related medicines in India during the quarter, COVID-related opportunistic portfolio recorded a decline in the revenues during the quarter, both on a sequential and on a year-on-year basis.
The consumer wellness business maintained its leadership positions in 5 out of these 7 brands in their respective categories. Overall, the India geography, which contributed 41% to the consolidated revenue during the quarter posted a growth of 12% on a year-on-year basis, excluding sales of COVID-related products, generics portfolio and divested products. Contribution of the India geography in consolidated revenues has gone up to 41.8% during the April, December 2021 period from 37% during the April, December 2020 period.
With that, let me quickly run you through the financial numbers for the quarter gone by. During the quarter, we posted a consolidated revenue of INR 36.55 billion, up 1% year-on-year. Excluding the COVID-related revenues, growth was 5% on a year-on-year basis. Consolidated EBITDA for the quarter was INR 7.5 billion, and the EBITDA margins were...